DENIAL CODES

Denial code M107

Remark code M107 indicates a payment reduction due to an ESRD patient's 90-day average hematocrit level exceeding 36.5%.

Accelerate your revenue cycle

Boost patient experience and your bottom line by automating patient cost estimates, payer underpayment detection, and contract optimization in one place.

Get a Demo

What is Denial Code M107

Remark code M107 indicates that the payment has been adjusted because the 90-day rolling average hematocrit level for a patient undergoing End-Stage Renal Disease (ESRD) treatment has exceeded the threshold of 36.5%. This suggests that the provider's reimbursement for services related to the patient's hematocrit management is being reduced due to the patient's average levels being above the established limit for the specified time period.

Common Causes of RARC M107

Common causes of code M107 are:

1. The patient's laboratory results indicate that the average hematocrit level over a 90-day period is above the threshold of 36.5%, which is considered higher than the standard for patients with End-Stage Renal Disease (ESRD) undergoing dialysis.

2. There may have been a data entry error or misreporting of the hematocrit levels, leading to an incorrect calculation of the 90-day rolling average.

3. The healthcare provider may not have adjusted the ESRD patient's treatment plan appropriately to maintain hematocrit levels within the recommended range, resulting in consistently high readings.

4. The patient could be receiving erythropoiesis-stimulating agents (ESAs) or other treatments that affect red blood cell production and hematocrit levels, and the dosing may need to be evaluated.

5. There may be inconsistencies or timing issues in the reporting of hematocrit levels, with some tests possibly being missed or not reported within the correct timeframe, affecting the rolling average calculation.

6. The patient might have a concurrent medical condition or could be taking medications that influence hematocrit levels, which has not been adequately accounted for in their treatment plan.

Ways to Mitigate Denial Code M107

Ways to mitigate code M107 include implementing a robust patient monitoring system to track the hematocrit levels of ESRD patients consistently. Ensure that treatment plans are adjusted in real-time based on the patient's current hematocrit levels to keep them within the acceptable range. Regularly educate staff on the importance of managing hematocrit levels and the financial implications of exceeding the threshold. Additionally, utilize data analytics to identify trends that may lead to higher hematocrit levels and take proactive measures to address these issues. It's also crucial to have a system in place for thorough documentation and coding practices that accurately reflect the patient's condition and the services provided.

How to Address Denial Code M107

The steps to address code M107 involve several key actions to ensure proper billing and reimbursement for ESRD-related services. First, review the patient's medical records to confirm the accuracy of the reported hematocrit levels. If the levels are correctly reported, evaluate the necessity of the treatment regimen that led to the elevated hematocrit and consider adjusting the treatment plan to maintain hematocrit levels within the acceptable range. Communicate with the nephrologist or healthcare provider overseeing the patient's ESRD treatment to discuss the findings and any potential changes to the care plan.

Next, audit your billing process to ensure that the hematocrit levels are being reported correctly and at appropriate intervals. If an error in reporting is discovered, correct the claim with accurate hematocrit levels and resubmit it to the payer. Additionally, implement a system to monitor hematocrit levels for ESRD patients regularly, ensuring that they stay within the recommended range to prevent future payment reductions.

If the treatment provided was medically necessary despite the elevated hematocrit levels, prepare and submit a detailed appeal to the payer. This appeal should include a thorough explanation and supporting documentation from the patient's medical records, such as physician notes and lab results, to justify the medical necessity of the treatment.

Finally, educate the clinical staff on the importance of managing ESRD patients' hematocrit levels to comply with payer guidelines and avoid future payment reductions. This may involve ongoing training about best practices in ESRD care and the financial implications of not adhering to established hematocrit thresholds.

CARCs Associated to RARC M107

Improve your financial performance while providing a more transparent patient experience

Full Page Background